The Best-Selling Peptides Right Now

operators ask this question expecting a leaderboard. the honest answer is that best-selling depends on which regulatory lane you are operating in, because the products that generate the most revenue and the products that are easiest to sell are not the same products. so this is organized by lane, with what each one demands of you operationally.

no dosing, protocols, or usage guidance anywhere in here. where products are research use only, that is stated. where products are prescription drugs, that is stated. this is a market and business guide and it is not medical or legal advice.

tier one: the revenue drivers (prescription lane)

semaglutide and tirzepatide are, by a very large margin, the biggest revenue generators available to a med spa right now. demand intensity, pricing power, and monthly repeat behavior are all at levels this industry has not previously seen.

they are also prescription drugs in the united states. that means the entire business is a licensed-provider care model: state-by-state provider licensure, a genuine clinical evaluation that can result in a decline, licensed pharmacy dispensing, corporate practice of medicine structuring, and adverse event handling. the compounded channel has been under sustained pressure as shortage-era flexibility narrowed, and the research-use-only gray channel is the fastest way to lose your payment processing and attract enforcement. we tell operators to stay out of it.

• —highest revenue per customer and best repeat behavior in the category
• —highest structural requirement — you are running a medical business, not a product business
• —high-risk payment processing mandatory, with a live backup processor
• —Meta weight loss policy applies: no before-and-afters, no outcome promises, age-restricted targeting
• —margin is decided by month-three and month-six cohort retention, not by unit price

tier two: the search demand leaders (research-use-only lane)

bpc-157 is the demand king of the research channel. it carries more compound-specific search volume than anything else in the lane, and it is the product people search by name with buying intent. it is not fda approved, is not a dietary ingredient, and the fda has signaled it is not appropriate for 503A compounding — so it lives in the research-use-only channel with not-for-human-consumption labeling and no claims of any kind.

tb-500 is the reliable second purchase. lower search volume, higher intent traffic, and consistently one of the top attach and bundle products in a research catalog. it does not carry cold acquisition well; it earns its keep in cart and post-purchase.

the growth hormone secretagogue family — ipamorelin, cjc-1295, sermorelin, tesamorelin and related compounds — represents a meaningful block of category demand. worth noting that their statuses differ significantly from one another: some have prescription drug status or compounding pathways that others do not, and treating them as one undifferentiated group is a compliance error. verify each compound individually with counsel before adding it to a catalog.

and a note on what not to sell: there are compounds with real search demand in this category that carry serious safety and regulatory baggage — melanotan-type compounds are the usual example. search volume is not a reason to carry something. if a compound's presence in your catalog would embarrass you in a deposition, do not carry it.

tier three: the best margin-to-risk ratio (med spa lane)

if you want the products with the strongest combination of demand, margin, and low regulatory drag, this is the tier, and it is the one most med spas under-invest in.

1. 1.NAD+ — high perceived value, existing consumer awareness, natural repeat cadence, and it attracts the longevity buyer who is the highest-LTV client profile in aesthetics. clinical formats need your provider layer; oral and sublingual formats can be shippable, with the caveat that some precursor ingredients have contested supplement status worth verifying
2. 2.glutathione — one of the highest attach rates on any med spa menu, with a clean extension into topical, oral, and liposomal shippable formats. injectable and IV formats stay inside the medical layer and never carry cosmetic lightening claims in advertising
3. 3.topical GHK-Cu — the only peptide on this list with a genuinely normal consumer retail path. cosmetic framework, standard payment processing, ordinary skincare advertising within cosmetic claim limits, and a product that physically runs out so subscription works

the processing point on that third item is worth several margin points on its own. moving a SKU from high-risk to standard processing is real money, and topical ghk-cu is one of the few ways to do it in this category.

how to read demand signals yourself

leaderboards go stale. build the capability to read the market instead of relying on someone else's ranking.

• —compound-name search volume with commercial modifiers tells you acquisition potential; benefit-term search tells you education burden
• —your own cart co-purchase data is the best attach signal in existence and most brands never look at it
• —competitor catalog changes are a lagging but useful indicator — when several serious brands quietly drop a SKU, find out why before you add it
• —processor and platform posture is a leading indicator of regulatory attention. when acquiring banks start declining a category, enforcement conversation usually follows
• —creator and podcast mention volume predicts search demand by roughly a quarter, which is enough lead time to get inventory in place

the catalog structure that actually works

the ranking matters less than the shape. across the brands we have scaled, the pattern that performs is consistent.

1. 1.one acquisition driver — the product with real search demand that you are willing to spend cold traffic against
2. 2.two to four high-attach products that raise AOV at essentially zero incremental acquisition cost
3. 3.one subscription anchor with a natural consumption cycle, because recurring revenue is what makes CAC affordable
4. 4.one or two proprietary bundles or blends that cannot be price-compared and give you a product that is genuinely yours
5. 5.a deliberately short tail — every additional SKU splits your creative budget, your inventory capital, and your testing cadence

most struggling catalogs we audit have the opposite shape: fifteen single compounds, no attach strategy, no subscription, nothing proprietary, and a creative budget spread so thin that no product ever gets enough testing volume to find a winner.

the best-selling peptide in your catalog is whichever one you built a second and third purchase around. the compound matters less than the structure.

what we would launch with today

for a med spa with a licensed medical layer already in place: a glp-1 program as the demand engine, nad+ as the high-ticket in-clinic service, glutathione as the scripted attach, and a topical ghk-cu retail line as the shippable, standard-processing, subscription-friendly margin layer. that combination gives you one product that acquires, one that raises ticket, one that attaches, and one that recurs without labor.

for a brand operating purely in the research-use-only lane: bpc-157 as the acquisition driver, tb-500 as the attach, one proprietary blend for AOV and differentiation, and a genuinely serious verification program — lot-linked COAs, independent testing, published batch data — as the actual brand. in that lane, verification is the product.